Published in J Clin Invest on June 01, 1974
Studies of the macrophage complement receptor. Alteration of receptor function upon macrophage activation. J Exp Med (1975) 7.87
Tumor-promoting phorbol esters stimulate C3b and C3b' receptor-mediated phagocytosis in cultured human monocytes. J Exp Med (1982) 7.10
Enhanced allergic tissue injury in Goodpasture's syndrome by intercurrent bacterial infection. Br Med J (1977) 1.92
A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood (2012) 1.45
Receptor specific clearance by the reticuloendothelial system in chronic liver diseases. Demonstration of defective C3b-specific clearance in primary biliary cirrhosis. J Clin Invest (1978) 1.45
Modification of glomerular immune complex deposition in mice by activation of the reticuloendothelial system. J Clin Invest (1981) 0.96
Demonstration of defective C3-receptor-mediated clearance by the reticuloendothelial system in patients with acquired immunodeficiency syndrome. J Clin Invest (1987) 0.92
C5a and Fcgamma receptors: a mutual admiration society. J Clin Invest (2006) 0.87
Immunomodulatory effects of recombinant BCG expressing MSP-1C of Plasmodium falciparum on LPS- or LPS+IFN-γ-stimulated J774A.1 cells. Hum Vaccin Immunother (2014) 0.75
Cellular resistance to infection. J Exp Med (1962) 30.96
Receptors for complement of leukocytes. J Exp Med (1968) 11.57
Immune hemolysis: a simplified method for the preparation of EAC'4 with guinea pig or with human complement. J Immunol (1967) 8.06
THE IN VITRO DIFFERENTIATION OF MONONUCLEAR PHAGOCYTES. II. THE INFLUENCE OF SERUM ON GRANULE FORMATION, HYDROLASE PRODUCTION, AND PINOCYTOSIS. J Exp Med (1965) 7.97
The host response to Calmette-Guérin bacillus infection in mice. J Exp Med (1969) 7.74
Human monocytes: distinct receptor sites for the third component of complement and for immunoglobulin G. Science (1968) 7.70
Red cells coated with immunoglobulin G: binding and sphering by mononuclear cells in man. Science (1967) 6.42
Complement dependent immune phagocytosis. I. Requirements for C'1, C'4, C'2, C'3. Exp Cell Res (1968) 6.20
Phagocytosis of immune complexes by macrophages. Different roles of the macrophage receptor sites for complement (C3) and for immunoglobulin (IgG). J Exp Med (1972) 6.13
Receptor sites of human monocytes for IgG. Int Arch Allergy Appl Immunol (1968) 4.07
The role of the reticuloendothelial system in the host reaction to neoplasia. Cancer Res (1961) 3.86
The complement system of man. I. N Engl J Med (1972) 3.09
The macrophage receptor for IgG: number and affinity of binding sites. J Immunol (1973) 2.91
Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites. J Clin Invest (1972) 2.82
Forssman antigen and antibody: preparation of water soluble antigen and measurement of antibody concentration by precipitin analysis, by C'1a fixation and by hemolytic activity. J Immunol (1966) 1.95
Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum. J Clin Invest (1972) 1.82
The effects of steroid hormones on macrophage activity. Int Rev Cytol (1969) 1.78
Anemia and the spleen. N Engl J Med (1958) 1.75
Effect of zymosan on endotoxin toxicity in mice. Proc Soc Exp Biol Med (1959) 1.74
The in vivo behaviour of complement-coated red cells: studies in C6-deficient, C3-depleted and normal rabbits. Clin Exp Immunol (1970) 1.60
Red-cell antibodies in acquired hemolytic anemia with negative antiglobulin serum tests. N Engl J Med (1971) 1.51
Destruction of injured red cells in vivo. Am J Med (1966) 1.49
PROLIFERATIVE RESPONSE OF THE SPLEEN AND LIVER TO HEMOLYSIS. J Exp Med (1965) 1.46
REGULATION OF SPLEEN GROWTH AND SEQUESTERING FUNCTION. J Clin Invest (1963) 1.32
Hypersplenism due to infection. A study of five cases manifesting hemolytic anemia. N Engl J Med (1961) 1.32
Effects of corticosteroids and splenectomy on the immune clearance and destruction of erythrocytes. J Clin Invest (1973) 1.24
The alternate complement pathway in cell damage: antibody-mediated cytolysis of erythrocytes and nucleated cells. J Immunol (1972) 1.12
The reticulo-endothelial system and resistance to bacterial infection. Scott Med J (1961) 1.07
Autoimmune haemolytic anaemias. Br Med J (1970) 1.05
Anemia and the spleen. N Engl J Med (1958) 1.03
Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N Engl J Med (1979) 4.52
Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu Rev Immunol (1991) 4.27
Analysis of cellular and protein content of broncho-alveolar lavage fluid from patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. J Clin Invest (1977) 4.21
Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med (1996) 3.89
Sjögren's syndrome (Sicca syndrome): current issues. Ann Intern Med (1980) 3.81
Receptors for complement and immunoglobulin on human leukemic cells and human lymphoblastoid cell lines. J Clin Invest (1972) 3.64
The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J Immunol (1974) 3.38
Decay-accelerating factor: biochemistry, molecular biology, and function. Annu Rev Immunol (1989) 3.20
Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med (1976) 3.10
Evidence for distinct intracellular pools of receptors for C3b and C3bi in human neutrophils. J Immunol (1985) 3.02
Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med (1976) 2.96
Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. J Exp Med (1986) 2.94
Human neutrophils increase expression of C3bi as well as C3b receptors upon activation. J Clin Invest (1984) 2.88
Measles virus spread and pathogenesis in genetically modified mice. J Virol (1998) 2.84
Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites. J Clin Invest (1972) 2.82
Molecular cloning and chromosomal localization of human membrane cofactor protein (MCP). Evidence for inclusion in the multigene family of complement-regulatory proteins. J Exp Med (1988) 2.75
Receptors for immunoglobulin and complement on human alveolar macrophages. J Immunol (1975) 2.74
Membrane cofactor protein (MCP or CD46) is a cellular pilus receptor for pathogenic Neisseria. Mol Microbiol (1997) 2.67
The regulators of complement activation (RCA) gene cluster. Adv Immunol (1989) 2.63
Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement. Proc Natl Acad Sci U S A (1987) 2.62
A new one-step method for the functional assay of the fourth component (C4) of human and guinea pig complement. J Immunol (1974) 2.60
Kinetic analysis of chemotactic factor generation in human serum via activation of the classical and alternate complement pathways. Clin Immunol Immunopathol (1975) 2.56
Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science (1990) 2.49
Plasma fibronectin enhances phagocytosis of opsonized particles by human peripheral blood monocytes. J Exp Med (1983) 2.49
Bactericidal and opsonic properties of C4-deficient guinea pig serum. J Immunol (1972) 2.48
Control of the complement system. Adv Immunol (1996) 2.43
A receptor for the third component of complement in the human renal glomerulus. J Exp Med (1975) 2.39
A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia. J Clin Invest (1982) 2.33
Polymorphism of human erythrocyte C3b/C4b receptor. Proc Natl Acad Sci U S A (1983) 2.30
In vitro studies of complement function in sera of C4-deficient guinea pigs. J Exp Med (1971) 2.29
Impaired immune response of splenectomised patients to polyvalent pneumococcal vaccine. Lancet (1981) 2.29
Expression of specific binding sites on Candida with functional and antigenic characteristics of human complement receptors. J Immunol (1986) 2.28
Nodular lymphoma--evidence for origin from follicular B lymphocytes. N Engl J Med (1974) 2.26
Defective Fc-receptor functions associated with the HLA-B8/DRw3 haplotype: studies in patients with dermatitis herpetiformis and normal subjects. N Engl J Med (1981) 2.19
Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2. Microb Pathog (1987) 2.15
The effect of temperature on the reactivity of guinea-pig complement with gamma G and gamma M haemolytic antibodies. Immunology (1970) 2.14
Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med (1995) 2.12
Human genes for three complement components that regulate the activation of C3 are tightly linked. J Exp Med (1985) 2.12
Identification of an additional class of C3-binding membrane proteins of human peripheral blood leukocytes and cell lines. Proc Natl Acad Sci U S A (1985) 2.11
Characterization of C1q receptor expression on human phagocytic cells: effects of PDBu and fMLP. J Immunol (1986) 2.09
Multiple isoforms of CD46 (membrane cofactor protein) serve as receptors for measles virus. Proc Natl Acad Sci U S A (1994) 2.08
Systemic capillary leak syndrome and monoclonal IgG gammopathy; studies in a sixth patient and a review of the literature. Medicine (Baltimore) (1977) 2.07
The localization of non-microbial antigens in the draining lymph nodes of tolerant, normal and primed rabbits. Immunology (1967) 2.07
Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet (1991) 2.05
Ontogeny of B lymphocytes. II. Relative rates of appearance of lymphocytes bearing surface immunoglobulin and complement receptors. J Exp Med (1974) 2.03
Studies of the molecular mechanisms of C3b inactivation and a simplified assay of beta 1H and the C3b inactivator (C3bINA). J Immunol (1979) 2.01
In vivo studies in C4-deficient guinea pigs. J Exp Med (1971) 2.00
Complement and bacteria: chemistry and biology in host defense. Annu Rev Immunol (1984) 1.87
The critical role of complement in experimental pneumococcal sepsis. J Infect Dis (1980) 1.87
Membrane cofactor protein (CD46) is a keratinocyte receptor for the M protein of the group A streptococcus. Proc Natl Acad Sci U S A (1995) 1.86
Dissecting sites important for complement regulatory activity in membrane cofactor protein (MCP; CD46). J Biol Chem (2000) 1.84
Complement depletion in cryptococcal sepsis. J Immunol (1978) 1.82
Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum. J Clin Invest (1972) 1.82
The complement system in host defense and inflammation. Rev Infect Dis (1980) 1.80
NIH Conference: Immunoglobulin G Fc receptor-mediated clearance in autoimmune diseases. Ann Intern Med (1983) 1.79
Molecular characterization of the Ss and Slp (C4) proteins of the mouse H-2 complex: subunit composition, chain size polymorphism, and an intracellular (PRO-Ss) precursor. J Immunol (1978) 1.75
Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity. J Exp Med (1987) 1.74
A new complement-mediated cytolytic mechanism--the C1-bypass activation pathway. Proc Natl Acad Sci U S A (1973) 1.74
C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I. J Exp Med (1984) 1.74
Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N Engl J Med (1972) 1.73
Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade. J Immunol (1986) 1.72
Membrane cofactor protein of complement is present on human fibroblast, epithelial, and endothelial cells. J Clin Invest (1989) 1.70
Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun (2011) 1.70
Functional properties of membrane cofactor protein of complement. Biochem J (1989) 1.68
Polymorphism of the human C3b/C4b receptor. Identification of a third allele and analysis of receptor phenotypes in families and patients with systemic lupus erythematosus. J Exp Med (1984) 1.68
C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha. J Exp Med (1988) 1.67
Decay-accelerating factor functions as a signal transducing molecule for human T cells. J Immunol (1988) 1.67
Opsonic requirements for intravascular clearance after splenectomy. N Engl J Med (1981) 1.65
Complement factor C3 deposition and serum resistance in isogenic capsule and lipooligosaccharide sialic acid mutants of serogroup B Neisseria meningitidis. Infect Immun (1997) 1.65
Hereditary deficiency of the sixth component of complement in man. I. Immunochemical, biologic, and family studies. J Clin Invest (1974) 1.65
Measles virus and C3 binding sites are distinct on membrane cofactor protein (CD46). Proc Natl Acad Sci U S A (1995) 1.64
Contribution of the repeating domains of membrane cofactor protein (CD46) of the complement system to ligand binding and cofactor activity. J Immunol (1991) 1.63
The role of antibody and complement in the reticuloendothelial clearance of pneumococci from the bloodstream. Rev Infect Dis (1983) 1.63
Generation of isogenic K54 capsule-deficient Escherichia coli strains through TnphoA-mediated gene disruption. Mol Microbiol (1993) 1.63
Bladder toxicity with chronic oral cyclophosphamide therapy in nonmalignant disease. Arthritis Rheum (1973) 1.61
The subunits in rabbit anti-Forssman IgM antibody. J Exp Med (1968) 1.60
A simple method for the determination of complement receptor-bearing mononuclear cells. J Immunol (1976) 1.59
Capsule production and growth phase influence binding of complement to Staphylococcus aureus. Infect Immun (2001) 1.59
Membrane cofactor protein (MCP; CD46): isoform-specific tyrosine phosphorylation. J Immunol (2000) 1.59
Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J Gen Virol (1997) 1.59
Response of variant hereditary angioedema phenotypes to danazol therapy. Genetic implications. J Clin Invest (1979) 1.58
Acquired C1 esterase inhibitor deficiency and angioedema: a review. Medicine (Baltimore) (1979) 1.57
Lack of binding of human C3, in its native state, to C3b receptors. J Immunol (1981) 1.57
Distribution of membrane cofactor protein of complement on human peripheral blood cells. An altered form is found on granulocytes. Eur J Immunol (1988) 1.55
Hereditary vascular retinopathy, cerebroretinal vasculopathy, and hereditary endotheliopathy with retinopathy, nephropathy, and stroke map to a single locus on chromosome 3p21.1-p21.3. Am J Hum Genet (2001) 1.54
Studies on the in vivo effects of antibody. Interaction of IgM antibody and complement in the immune clearance and destruction of erythrocytes in man. J Clin Invest (1974) 1.54
Induction of a transient elevation in intracellular levels of adenosine-3',5'-cyclic monophosphate by chemotactic factors: an early event in human neutrophil activation. J Immunol (1980) 1.54
Modulation of FcR function by complement: subcomponent C1q enhances the phagocytosis of IgG-opsonized targets by human monocytes and culture-derived macrophages. J Immunol (1987) 1.51
Regulation of complement activity by vaccinia virus complement-control protein. J Infect Dis (1992) 1.49
Studies on the fibronectin receptors of human peripheral blood leukocytes. Morphologic and functional characterization. J Exp Med (1984) 1.48
Evidence that rabbit gamma G haemolysin in capable of utilizing guinea-pig complement more efficiently than rabbit gamma M haemolysin. Immunology (1970) 1.48
Mapping of the region of complement receptor (CR) 1 required for Plasmodium falciparum rosetting and demonstration of the importance of CR1 in rosetting in field isolates. J Immunol (2000) 1.48